Quibim closes $50m Series A funding round
The round was led by Asabys (through its fund Sabadell Asabys II) and Buenavista Equity Partners (through the BHG I fund, created in partnership with Columbus Venture Partners), and joined by UI Investissement, and GoHub Ventures as new investors.
Current investors Amadeus Capital Partners, APEX Ventures, Partech, Adara Ventures, Leadwind (KFund’s early growth fund), Tony Fadell’s Build Collective, and serial biotech entrepreneur Dr. Jonathan Milner also participated.
Valencia-headquartered Quibim also has offices in Barcelona, Cambridge and New York. The company says it will use the Series A funding to establish a strong US presence, building on its success in Europe, through strategic collaborations with hospitals and pharmaceutical companies.
Quibim CEO and co-founder, Dr. Ángel Alberich-Bayarri said: “Quibim’s mission is to turn imaging into a catalyst for precision health, and we are deeply grateful to both our new and current investors for their support.
“Our global expansion into the US is a critical milestone as we work with pharmaceutical leaders and healthcare providers to unlocking the power of imaging to revolutionise diagnostics and improve patient outcomes.”
Quibim is on a mission to unlock a complete, non-invasive understanding of every tissue point in the human body, at any moment in time. To achieve this, the company develops foundational AI models applied to imaging that extract actionable insights from MRI, CT, and PET scans. These insights enable precise characterisation of phenotypes and prediction of outcomes in areas such as oncology, immunology, neurology and metabolic disorders.
This is the pathway toward achieving human digital twins, dynamic models that not only reflect and allow health monitoring but also enhance patient stratification, improve the success rates of drug development programs, and enable treatment testing before application.
Today, the company is building digital twins at the organ and lesion level, exemplified by its QP-Brain, QP-Prostate, and QP-Liver solutions.
However, as the volume of whole-body scans and related imaging data continues to grow, in the coming years Quibim models will analyse the entire body. The vision of the company is to catalyse this revolutionary step in healthcare by merging imaging technologies, computing, and AI.
With over 170 installations worldwide, including institutions like Mass General Brigham and Stanford, and regulatory clearances across the US, EU, UK, and other regions, Quibim's technology bridges the gap between research, clinical practice, and drug development.
“The foundational research done by Quibim’s team has not only informed industry standards, but also led to the company pioneering an approach to combining radiomics and deep learning that is now a standard of its own,” said Pierre Socha, Partner at Amadeus Capital Partners. “This platform approach was novel at the time of our first investment and proved to be the right strategy for rapid scale-up.”
Last year, Philips announced a global partnership with Quibim to integrate its AI models into MR scanners, while the company also secured strategic alliances with leading biopharma giants such as Merck KGaA and Novartis.
Guillem Masferrer, Partner at Asabys Partner said: Asabys is thrilled to support Quibim in transforming the imaging diagnostics space. Their ability to combine AI with imaging biomarker discovery addresses critical unmet needs in oncology, neurology, and beyond. We are confident that Quibim’s innovative solutions will have a profound impact on global healthcare.”
José Mesa, Partner at Columbus and Buenavista’s representative on the Board, added: “Quibim’s technology exemplifies the next wave of precision medicine. Their impressive track record with global pharmaceutical partnerships, including partnerships with companies such as Merck KGaA and Philips, exemplify Quibim’s role in transforming imaging data into valuable predictions for clinical trials and treatment planning. We expect that as Quibim develops its pipeline of companion diagnostic tools, we will see tremendous momentum for its technology and products.”
Build Collective Principal, Tony Fadell said: “Excited that Quibim’s AI enabled insights from MRI, CT and PET scans are coming to the US! Their FDA approved precision analysis is already being used by doctors to detect early signs of diseases like cancer and help measure treatment response. Quibim has truly advanced precision medicine around the world!”